CryoPort (CYRX) Competitors $7.19 -0.24 (-3.23%) Closing price 04:00 PM EasternExtended Trading$7.29 +0.10 (+1.39%) As of 06:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CYRX vs. TVTX, EWTX, EVO, BHVN, MESO, ANIP, HROW, PAHC, ABCL, and COGTShould you be buying CryoPort stock or one of its competitors? The main competitors of CryoPort include Travere Therapeutics (TVTX), Edgewise Therapeutics (EWTX), Evotec (EVO), Biohaven (BHVN), Mesoblast (MESO), ANI Pharmaceuticals (ANIP), Harrow (HROW), Phibro Animal Health (PAHC), AbCellera Biologics (ABCL), and Cogent Biosciences (COGT). These companies are all part of the "pharmaceutical products" industry. CryoPort vs. Its Competitors Travere Therapeutics Edgewise Therapeutics Evotec Biohaven Mesoblast ANI Pharmaceuticals Harrow Phibro Animal Health AbCellera Biologics Cogent Biosciences Travere Therapeutics (NASDAQ:TVTX) and CryoPort (NASDAQ:CYRX) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk. Which has more volatility and risk, TVTX or CYRX? Travere Therapeutics has a beta of 0.72, indicating that its stock price is 28% less volatile than the S&P 500. Comparatively, CryoPort has a beta of 1.89, indicating that its stock price is 89% more volatile than the S&P 500. Do institutionals & insiders hold more shares of TVTX or CYRX? 92.9% of CryoPort shares are owned by institutional investors. 4.2% of Travere Therapeutics shares are owned by insiders. Comparatively, 10.0% of CryoPort shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Is TVTX or CYRX more profitable? CryoPort has a net margin of -50.15% compared to Travere Therapeutics' net margin of -82.88%. CryoPort's return on equity of -11.03% beat Travere Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Travere Therapeutics-82.88% -1,179.73% -41.10% CryoPort -50.15%-11.03%-5.54% Which has stronger earnings & valuation, TVTX or CYRX? CryoPort has lower revenue, but higher earnings than Travere Therapeutics. Travere Therapeutics is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTravere Therapeutics$233.18M6.14-$321.55M-$2.81-5.73CryoPort$228.38M1.58-$114.76M-$2.34-3.07 Does the media refer more to TVTX or CYRX? In the previous week, Travere Therapeutics had 8 more articles in the media than CryoPort. MarketBeat recorded 12 mentions for Travere Therapeutics and 4 mentions for CryoPort. CryoPort's average media sentiment score of 1.21 beat Travere Therapeutics' score of 0.44 indicating that CryoPort is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Travere Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral CryoPort 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer TVTX or CYRX? Travere Therapeutics currently has a consensus target price of $32.14, suggesting a potential upside of 99.52%. CryoPort has a consensus target price of $10.88, suggesting a potential upside of 51.25%. Given Travere Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Travere Therapeutics is more favorable than CryoPort.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Travere Therapeutics 0 Sell rating(s) 2 Hold rating(s) 13 Buy rating(s) 0 Strong Buy rating(s) 2.87CryoPort 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.75 SummaryCryoPort beats Travere Therapeutics on 10 of the 16 factors compared between the two stocks. Get CryoPort News Delivered to You Automatically Sign up to receive the latest news and ratings for CYRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CYRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CYRX vs. The Competition Export to ExcelMetricCryoPortTRANS IndustryTransportation SectorNASDAQ ExchangeMarket Cap$372.52M$5.74B$7.32B$9.41BDividend YieldN/A2.30%922.82%4.03%P/E Ratio-3.079.5612.3320.09Price / Sales1.581.19543.5099.01Price / CashN/A10.717.9158.27Price / Book0.972.942.135.65Net Income-$114.76M$184.70M$568.35M$257.91M7 Day Performance-4.77%-2.35%-1.23%2.09%1 Month Performance6.05%0.24%3.59%11.13%1 Year Performance-15.51%-6.40%3.13%18.40% CryoPort Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CYRXCryoPort2.4035 of 5 stars$7.19-3.2%$10.88+51.3%-12.3%$372.52M$228.38M-3.071,186Analyst RevisionTVTXTravere Therapeutics3.7272 of 5 stars$16.91+2.7%$32.14+90.1%+60.4%$1.50B$233.18M-6.02460News CoverageAnalyst RevisionEWTXEdgewise Therapeutics1.4953 of 5 stars$13.93+0.7%$40.00+187.2%-36.1%$1.47BN/A-8.9960EVOEvotec1.9928 of 5 stars$4.12+1.2%$5.93+44.0%-11.3%$1.46B$862.40M0.004,827Gap UpBHVNBiohaven3.3597 of 5 stars$14.18+1.8%$58.46+312.2%-58.2%$1.45BN/A-1.52239Trending NewsMESOMesoblast1.6926 of 5 stars$11.17+0.5%$18.00+61.1%+67.2%$1.43B$5.90M0.0080News CoveragePositive NewsAnalyst DowngradeGap UpANIPANI Pharmaceuticals3.7657 of 5 stars$65.19+0.4%$78.88+21.0%+8.0%$1.41B$674.07M-51.33600HROWHarrow2.3814 of 5 stars$35.62+2.0%$63.83+79.2%+43.7%$1.31B$199.61M-63.61180Trending NewsAnalyst RevisionPAHCPhibro Animal Health4.0498 of 5 stars$31.54+2.4%$24.40-22.6%+56.3%$1.28B$1.02B40.441,940News CoverageABCLAbCellera Biologics2.3189 of 5 stars$4.24+5.7%$8.75+106.4%+15.7%$1.27B$28.83M-7.57500COGTCogent Biosciences3.5461 of 5 stars$11.09+1.0%$18.00+62.3%+35.9%$1.26BN/A-6.0380Trending NewsAnalyst ForecastAnalyst RevisionGap Up Related Companies and Tools Related Companies Travere Therapeutics Competitors Edgewise Therapeutics Competitors Evotec Competitors Biohaven Competitors Mesoblast Competitors ANI Pharmaceuticals Competitors Harrow Competitors Phibro Animal Health Competitors AbCellera Biologics Competitors Cogent Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CYRX) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredFREE BUY ALERT: These 3 tiny AI stocks could surgeWe're living in unprecedented times. Most people think it's too late to get into AI right now … That the...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CryoPort, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CryoPort With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CYRX Stock Alerts